Literature DB >> 9367401

IgA from HIV+ haemophilic patients triggers intracellular signals coupled to the cholinergic system of the intestine.

M E Sales1, L Sterin-Borda, M M de Bracco, M Rodriguez, M Narbaitz, E Borda.   

Abstract

IgA was obtained from HIV-infected haemophilic patients and the intracellular signals triggered by its reaction with isolated rat intestinal strips were studied. HIV+ IgA stained intestinal microvilli with a granular immunofluorescence pattern and bound to the muscarinic acetylcholine receptor (mAChR), displacing the specific muscarinic cholinergic antagonist QNB in a non-competitive manner. It triggered the signals that are the consequence of mAChR stimulation in the intestine. Thus, it decreased cAMP synthesis and increased guanosine 3':5'-cyclic monophosphate (cGMP) formation and phosphoinositide (PI) turnover of the intestine. In addition, it stimulated prostaglandin E2(PGE2) synthesis by intestinal strips. Through its effect on PGE2 synthesis, HIV+ IgA could have a dual action. On the one hand, it could enhance immunosuppression at a local level, favouring pathogen growth and subsequent intestinal dysfunction. On the other hand, PGE2 could directly increase intestinal motility and electrolyte/fluid loss. Both effects could be involved in intestinal damage in AIDS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367401      PMCID: PMC2265510          DOI: 10.1111/j.1365-2249.1997.tb08316.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Neutrophils and adjuvant arthritis.

Authors:  P A Ward
Journal:  Clin Exp Immunol       Date:  1997-02       Impact factor: 4.330

3.  A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate.

Authors:  B L Brown; J D Albano; R P Ekins; A M Sgherzi
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

Review 4.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; D R Webb
Journal:  Clin Immunol Immunopathol       Date:  1980-01

5.  Radioimmunoassay of prostaglandins and thromboxanes.

Authors:  E Granström; H Kindahl
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1978

6.  Pharmacological evidence for the existence of different subtypes of muscarinic acetylcholine receptors for phosphoinositide hydrolysis in neonatal versus adult rat atria.

Authors:  J J Camusso; L Sterin-Borda; M Rodriguez; S Bacman; E Borda
Journal:  J Lipid Mediat Cell Signal       Date:  1995-07

Review 7.  New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes.

Authors:  R J Mayer; L A Marshall
Journal:  FASEB J       Date:  1993-02-01       Impact factor: 5.191

8.  Modification of cholinergic-mediated cellular transmembrane signals by the interaction of human chagasic IgG with cardiac muscarinic receptors.

Authors:  J C Goin; C Perez Leiros; E Borda; L Sterin-Borda
Journal:  Neuroimmunomodulation       Date:  1994 Sep-Oct       Impact factor: 2.492

9.  Autoantibodies in HIV-infected patients that modulate the cholinergic activity of heart and gut tissue.

Authors:  M M de Bracco; E Borda; N Galassi; R Perez-Bianco; L Sterin-Borda
Journal:  Autoimmunity       Date:  1993       Impact factor: 2.815

10.  Role of prostaglandin E2 in alterations of the beta-adrenergic system from rat eclamptic uterus.

Authors:  M E Sales; E S Borda; L Sterin-Borda; A Arregger; E C Andrada
Journal:  Biochem Pharmacol       Date:  1995-09-28       Impact factor: 5.858

View more
  1 in total

1.  The impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohort.

Authors:  Francois N Slabbert; Brian H Harvey; Christiaan B Brink; Martie S Lubbe
Journal:  AIDS Res Ther       Date:  2015-04-14       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.